Mrs Camilla Macapili Languille (born 1983, Canadian citizen) was appointed Member of the Supervisory Board on 22 June 2022.
Camilla Macapili Languille is an investment expert with some 20 years of experience in business development, asset management and M&A in Europe, North America and Middle East and North Africa (MENA). She has worked in various areas of corporate finance and principal investment, with a focus on healthcare, technology and industrial companies.
Camilla Macapili Languille leads the unit for Life Sciences investments at Mubadala Investment Company ("MIC"), a sovereign wealth fund based in Abu Dhabi with total assets of some USD 250 billion. This unit invests in the international healthcare sector in the fields of pharmaceuticals, medical devices, life-science tools and diagnostics, healthcare IT, services, biotechnology and veterinary medicine, and in various asset classes (private equity, listed shares, funds). She is currently a member of the Direct Investments Committee of Mubadala and has a seat on the board of PCI Pharma, Rodenstock and the Envision Pharma Group.
Before founding the Life Sciences investment team, Camilla Macapili Languille managed the MIC investments in Advanced Micro Devices (“AMD”) and Globalfoundries and was responsible for business development in the technology sector. She also led MIC investments in two power plants in Oman and Algeria, a goldmine in Columbia and a district cooling plant, Tabreed, and was responsible for business development for MIC in the field of conventional energy.
Before joining Mubadala, Camilla Macapili Languille worked in M&A for Daiwa Capital and Société Générale in Paris, France, where she specialised in cross-border transactions in various sectors. She also worked as an investment manager at the London headquarters of the Virgin Group, where she managed the special situations portfolio, was involved in the establishment of Virgin Healthcare, and was a director of several companies.
Camilla Macapili Languille began her career in healthcare M&A at JPMorgan in New York and London, where she focused on pharma and biotech.
Camilla Macapili Languille holds a Bachelor of Economics & Political Science degree from Columbia University, which she completed summa cum laude in 2004. She grew up in an international environment and has lived in 14 countries on four continents. She speaks fluent English and French.
Her long-standing, wide-ranging experience in the pharmaceutical and biotech sectors mean she has extensive knowledge of the industry. Her particular investment expertise makes Ms Macapili Languille an ideal addition to the range of competences represented on the potential Supervisory Board of Evotec SE.
Latest update: June 2022